Clinical, economical and ethical aspects assessing therapy outcomes in patients with multiple myelomas of high cytogenetic risk

Author:

Zabolotneva YA1,Gurevich KG1

Affiliation:

1. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

Abstract

According to European authors, patients with multiple myeloma (MM) and high cytogenetic risk have shorter values of progression free survival (PFS) and overall survival (OS) as compared with standard hazard. More frequent hospitalizations mean potentially high expenses associated with management of patients with unfavorable cytogenetic risk. Cost and availability of treatment of oncological patients relate to one of pressing ethical issues. Another important aspect of this issue consists in an effective use of available approved modes of therapy in patients with various survival prognosis, which is especially critical for early lines of therapy. It has been proven that early administration of more effective modes based on individual characteristics both of a patient, and a disease will improve the total survival of patients. This will result in reduction of economic resources spent on selecting new modes of treatment in patients with a disease recurrence and correction of possible adverse effects and hospitalization.

Publisher

Pirogov Russian National Research Medical University

Subject

Law,Organizational Behavior and Human Resource Management,Economics and Econometrics,Industrial relations,Anthropology,Cultural Studies,History,Anthropology,Cultural Studies,General Mathematics,General Medicine,Infectious Diseases,Physics and Astronomy (miscellaneous),General Engineering,Atomic and Molecular Physics, and Optics,General Engineering,Statistical and Nonlinear Physics,General Physics and Astronomy,General Engineering

Reference31 articles.

1. Sonneveld P, Avet‑Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high‑risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016; 127: 2955–2962.

2. Abdallah N, Rajkumar SV, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Kumar SK. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer J. 2020 Aug 11; 10 (8): 82. DOI: 10.1038/ s41408–020–00348–5. PMID: 32782240; PMCID: PMC7419564.

3. Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005; 23: 3412–3420.

4. Palumbo A, Avet‑Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10; 33 (26): 2863–9. DOI: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3. PMID: 26240224; PMCID: PMC4846284.

5. Mayo Clinic. (2021). Mayo stratification for myeloma and risk‑adapted therapy: relapsed myeloma. Available from mSMART: A clear and simple guide for treating patients with multiple myeloma — Mayo Clinic (Accessed 9 December 2021).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3